• Home
• Defective Drug Index
• About A Drug Recall
• Contact A Defective Drug Lawyer

We Can Help.

Celebrex Risks

On December 17, 2004, Pfizer publicly announced that new clinical trial evidence has shown significant cardiovascular Celebrex risks. This evidence came out of a clinical study conducted by the National Cancer Institute to measure the effects of Celebrex on cancer. The trial was stopped short after preliminary evidence revealed that patients taking 400 to 800 milligrams of Celebrex were two and a half times more likely to suffer heart attack or cardiovascular stroke.

Pfizer announced that despite these Celebrex risks, a Celebrex recall is not being considered by the pharmaceutical giant who enjoys almost three million dollars in annual revenue from this blockbuster prescription drug. A Pfizer spokesperson announced that the company will take immediate steps to investigate Celebrex risks and report their findings to regulators, medical professionals and patients worldwide.

These reports of cardiovascular Celebrex risks ride in on the coattails of studies that found similar risks associated with two other COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDS). Vioxx was recalled in September 2004 after Merck clinical trials found that patients who had taken Vioxx for a year and a half were twice as likely to suffer adverse cardiovascular events as patients who were taking a sugar pill. Bextra, a drug very similar to Celebrex, has also been shown to cause elevated cardiovascular risks in heart surgery patients who were taking Bextra.

On several occasions Pfizer has announced that Celebrex risks did not include the same cardiovascular risks that were posed by Vioxx or Bextra use. Several studies prior to the most recent had concluded that cardiovascular Celebrex risks did not pose a threat to patients. However, other reports had indicated that Celebrex risks did include significant cardiovascular problems.

In October 2004 the New England Journal of Medicine published a report stating that Celebrex risks were similar to those of Vioxx. Three months after Celebrex was first approved to treat the severe pain associated with arthritis and menstrual cramps, The Wall Street Journal published a Celebrex risks report about the deaths of ten people that had been linked to Celebrex use. Of these ten fatalities, gastrointestinal bleeding was the cause in five cases, kidney problems in one, drug interaction in one, and heart attack in two. Though these Celebrex risks were never officially proven to be the cause of these deaths, these complications have all been cited as legitimate Celebrex risks.

In addition to cardiovascular complications, Celebrex risks also include ulcer development and severe allergic reaction in patients with an allergy to aspirin, other NSAIDs, and sulfa drugs. If you are currently taking Celebrex and are concerned about Celebrex risks you should speak with your doctor before making any changes to your treatment. If your doctor feels that Celebrex risks outweigh this drug's intended benefits, there are alternative medications which can be prescribed that do not carry the same Celebrex risks. If you experience any adverse health symptoms as a result of Celebrex use, you should seek medical attention.

If you have taken Celebrex arthritis drug and have suffered adverse reactions because of it, please contact us to speak with a lawyer for more information on Celebrex risks.

More Celebrex Resources

MedLine Plus Drug Information - Guide to prescription and over-the-counter medications provided by the United States Pharmacopeia.

Celebrex - A source of information about relief from arthritis pain including Osteoarthritis and Rheumatoid Arthritis.

• Reglan
• Raptiva
• Yaz Birth Control
• Nuvaring
• Duragesic Patch
• Heparin